Rigel Pharmaceuticals (RIGL) Equity Ratio (2010 - 2026)

Rigel Pharmaceuticals' Equity Ratio history runs 17 years deep, the most recent figure standing at 0.79 for Q1 2026.

• In Q1 2026, Equity Ratio rose 651.1% year-over-year to 0.79; the TTM figure through Mar 2026 stood at 0.79 (up 651.1% YoY), while the FY2025 annual figure was 0.76, up 3701.35% from the prior year.
• Equity Ratio was 0.79 for Q1 2026 at Rigel Pharmaceuticals, up from 0.76 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.79 in Q1 2026 to a low of 0.28 in Q3 2023.
• Historically, Equity Ratio has averaged 0.04 across 5 years, with a median of 0.1 in 2022.
• The sharpest annual moves came in 2023 and 2025: Equity Ratio plunged 735.86% in 2023, then soared 3701.35% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.1 in 2022, then tumbled by 140.97% to 0.24 in 2023, then jumped by 108.21% to 0.02 in 2024, then jumped by 3701.35% to 0.76 in 2025, then increased by 3.97% to 0.79 in 2026.
• The last three Equity Ratio figures came in at 0.79 (Q1 2026), 0.76 (Q4 2025), and 0.48 (Q3 2025), per Business Quant data.